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Introduction: A prospective study to evaluate the reliability of cystoscopy was performed 
with ﬂ  uorescence (photodynamic diagnosis, PDD) compared with standard white light (WL) 
cystoscopy in patients with solitary carcinoma in situ (CIS), undergoing BCG treatment.
Materials and methods: Between February 2004 and March 2006, 49 patients suffering 
from CIS were enrolled in the study. Patients age was 68.5 ± 13.5 years (mean ± SD) and all 
presented CIS alone at inclusion. All suspicious areas were biopsied either under white light or 
blue light. Urine cytology was peformed on each patient before endoscopy.
Results: Out of 49 patients enrolled, 15 (30.6%) presented with positive urinary cytology. Out 
of 18 patients positive to CIS at biopsy, 14 (77.7%) could be diagnosed exclusively by means 
of PDD cystoscopy and transurethral bladder resection and 4 (22.3%) during both standard 
and PDD cystoscopy. No additional CIS could be diagnosed by standard WL cystoscopy 
alone. The overall false positive rate for PDD accounted for 33.3% compared with 7.1% for 
WL cytoscopy. A statistical correlation was documented between the number of CIS ﬁ  ndings 
and PDD (r = 0.6976, p = 0.0002) while WL cystoscopy (r = 0.1870, p = 0.3816) and urinary 
cytology (r = 0.4965, p = 0.0136) correlated only weakly with CIS. The overall side effects 
related to the drugs were negligible overall.
Conclusions: These data show that PDD cystoscopy is more reliable than WL cytoscopy for the 
follow-up of CIS patients during BCG treatment. Long-term data and multicenter, prospective 
data are needed to assess the true impact on tumor recurrence and progression.
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Introduction
Carcinoma in situ (CIS) of the bladder still represents one of the most challenging 
issues in urological oncology. Urinary cytology and conventional cystoscopy with 
bladder mapping have represented the golden standard diagnostic tools for many years 
(Witjes 2004). In spite of their overall high sensitivity and speciﬁ  city, the incidence 
and prevalence of CIS have continued to be underestimated (Lamm 1992). Urinary 
cytology cannot provide information regarding the location and the extent of this 
tumor, and suffers from the limitations related to the subjective skill of the referral 
pathologist (Raitanen et al 2002). On the other hand, there is a general agreement 
that a delay in the recognition of this disease, mainly when resistant or recurrent after 
intravesical immunotherapy, can be responsible for tumor progression, as documented 
by the consistent amount of patients with positive lymph nodes at the time of radical 
cystectomy. To date, none of the new markers has proved to be superior to standard 
urinary cytology in improving our ability to detect and treat CIS (Sylvester et al 2005). 
Since the ﬁ  rst experience published in the 1990s, porphyrin-induced ﬂ  uorescence 
associated with cystoscopy (photodynamic diagnosis, PDD) or transurethral bladder 
resection (TUR), has progressively gained a relevant position among the diagnostic 
procedures and the endoscopic treatments of superﬁ  cial bladder cancer (Kriegmair 
et al 1995). Recent studies have provided indubitable evidence that PDD can actually Therapeutics and Clinical Risk Management 2007:3(6) 1004
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play a key role in the diagnosis of ﬂ  at lesions, either single 
tumor presentation or concurrent with papillary tumors (Zaak 
et al 2005). The very high sensitivity and the excellent safety 
proﬁ  le certainly represent the most relevant advantages 
of this approach. The non-negligible rate of false positive 
results, the uncertain reliability when performed during the 
follow-up of patients undergoing intravesical therapy, and the 
global cost are generally considered as the most consistent 
limitations of this procedure. Although several porphyrin-
derived drugs are under investigation for PDD, only two are 
currently used: 5-aminolevulinic acid (5-ALA), the ﬁ  rst to 
be introduced, and its more potent ester hexaminolevulinate 
(HAL) (Zaak et al 2005).
In this study we sought to compare the blue light cystos-
copy (PDD) with the standard white light (WL) cytoscopy, 
in a particular subgroup of patients suffering from CIS 
alone at inclusion and undergoing therapy with endovesical 
immunotherapy (Bacillus Calmette-Guérin, BCG).
Methods
Between February 2004 and March 2006, 49 patients 
suffering from CIS alone at the time of study inclusion 
undergoing BCG treatment (OncoTICE®, 50 mg, BCG TICE 
strain, 1 to 8 x 108 colony forming units per instillation dose) 
according to the SWOG (South Western Oncology Group) 
maintenance schedule, were enrolled in this prospective 
study. Primary endpoint of the study was to compare 
the reliability of PDD-guided bladder mapping with WL 
cytoscopy and urinary cytology for the followup of CIS 
patients under BCG treatment. All PDD procedures were 
carried out by the same surgeons (RC, RN).
The PDD-system components used were Richard 
Wolf (Germany) and Storz (GmbH, Tuttlingen, Germany) 
dedicated instruments. For both systems, the light source 
used to produce fluorescence excitation was a filtered 
white light ﬁ  tted with a xenon lamp (300 W) delivering a 
wavelength between 380 and 440 nm. All the examinations 
were performed using speciﬁ  c PDD telescopes (0°, 12°, 25°, 
and 70° according to the tumor location) and software for 
video-image reconstruction. All procedures were performed 
suing intravesical fluorescence-inducing drugs such as 
5-aminolevulinic acid (5-ALA hydrochloride 1.5 mg dissolved 
in 50 mL of 3.5% sodium monohydrogenophosphate solution; 
Medac GmbH, Wedel Germany-Shering) in 20 cases (40.9%) 
and HAL 85 mg (HAL hydrochloride; Hexvix®, Photocure™, 
GE Healthcare) in the other 29 (59.1%). After adequate time 
of bladder instillation, bladders were totally voided from any 
residual solution prior to starting the endoscopic procedure. 
A standard WL cystoscopy was always performed as a ﬁ  rst 
step of the evaluation and all suspicious areas were accurately 
described and reported on a bladder map. Thereafter, a 
ﬂ  uorescence cystoscopy was accurately performed and any 
suspicious area was reported on the same map. In addition, 
any side effect related to the drugs was described. Cold 
cup biopsies and/or deep biopsies were taken by standard 
resection and biopsies were collected from any suspicious 
area either under blue or white light. Whenever no suspicious 
areas could be seen, a standard random mapping including 
8 biopsies overall was completed.
Patients were recruited for the study at any moment of 
the SWOG maintenance schedule. Three weeks were deﬁ  ned 
as the minimum time between last bladder instillation and 
endoscopic evaluation. Table 1 shows patient characteristics 
including pre-study bladder cancer and history. All patients 
necessarily provided urinary cytology on three voided 
samples at time of the endoscopy. While cytological evalua-
tion was performed by different pathologists, all histological 
evaluations were systematically examined by the same uro-
pathologist blind to the study, according to the 1973 WHO 
diagnostic criteria. All patients signed an informed consent 
prior undergoing the procedure. Side effects were assessed 
directly by the hospital staff directly during hospitalization. 
The patients were seen on outpatient basis and verbally 
assessed for any post-operative complication.
Data were analyzed using commercially available sta-
tistical software and are presented as mean ± SD. For all 
statistical comparisons, signiﬁ  cance was deﬁ  ned as a p value 
of less than 0.05.
Results
The mean time of the bladder instillation was 160 min (range: 
100–180) and 85 min (range: 30–120) for 5-ALA and HAL 
respectively. In particular, only 3 patients who received HAL kept 
the drug for less than 60 min due to reduced bladder capacity.
Table 1 Patient characteristics (mean ± SD)
Number of patients  49
Mean age (years)  70 ± 12
Time from last bladder instillation (days)  68 ± 28
Number of bladder instillations/patient (BCG)  16 ± 10
Bladder cancer history
TaG1 + CIS  3
TaG2 + CIS  5
T1G2 + CIS  2
T1G3 + CIS  12
Previous CIS alone  27
Abbreviations: BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ.Therapeutics and Clinical Risk Management 2007:3(6) 1005
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Out of 49 patients enrolled, 15 (30.6%) presented with 
positive cytology at the time of investigation and overall 18 
(36.7%) resulted positive for CIS at bladder mapping. Among 
those, 14 (77.7%) were diagnosed exclusively by means of 
biopsies guided by PDD while 4 (22.2%) were diagnosed 
during both the standard and PDD cystoscopy. On the other 
hand, no additional CIS was diagnosed with standard cys-
toscopy only. In 9 cases of suspicious areas at ﬂ  uorescence 
cystoscopy, 7 cases were diagnosed as inﬂ  ammatory tissue 
and 2 as mild dysplasia. As a consequence, the overall false 
positive rate accounted for 33.3%. In particular there were 
5 PDD false positives in the 5-ALA group (35%) but in the 
HAL group there were 4 (22.7%, p < 0.005).
An overall statistical correlation could be found between 
the number of CIS documented by histology and ﬂ  uores-
cence (r = 0.6976, p = 0.0002) while white light (r = 0.1870, 
p = 0.3816) correlated only weakly with CIS detected and 
urinary cytology seemed to correlate with CIS (r = 0.4965, 
p = 0.0136). Furthermore, no correlation was observed 
between cytology and white light (r = 0.0374, p = 0.8623).
In two patients with positive cytology, no suspicious 
area within the bladder could be observed by both standard 
and PDD cystoscopy. According to the design of the 
study, these patients underwent random bladder mapping 
which deﬁ  nitively resulted negative for bladder cancer. 
A subsequent separate ureteral selective cytology was 
documented to be positive in both patients, suggesting proof 
of upper urinary tract CIS. No systemic side effects related 
to the procedure were reported while local side effects were 
referred as negligible from all patients.
Discussion
However easily deﬁ  ned, the ideal diagnostic tool for bladder 
cancer detection and monitoring is still far from being found. 
The ideal test should be simple to perform, affordable 
and should provide the highest levels of sensibility and 
speciﬁ  city. The association between urinary cytology and 
standard WL cystoscopy are still considered as the elective 
diagnostic approach for CIS of the bladder (Sylvester et al 
2005). However, the sensitivity and speciﬁ  city of urinary 
cytology vary throughout the literature due to its well 
known limitations, such as limited amount of retrieved 
cells, inter- and intra-observer variability, and alterations 
related to inadequate preservation of the voided specimens. 
In addition, as well known, pathologist interpretation can 
become misleading in cases of concomitant urinary infections 
and during intravesical chemo- or immuno-prophylaxis 
(Raitanen et al 2002). Moreover, evidence can be found in 
the literature attesting that standard bladder mapping with 
random biospies taken under white light has little value from 
both diagnostic and prognostic points of view (Kiemeney 
et al 1994; Sylvester et al 2005). Recent published guidelines 
(Sylvester et al 2005) have highlighted the increasing role 
of photodynamic endoscopy especially for the diagnosis of 
bladder CIS and dysplasia. On the other hand, PDD-guided 
TUR of papillary tumors seems to significantly reduce 
residual tumor, providing a positive impact on the reduction 
of the recurrence rate (Zaak et al 2005). The feasibility 
and superiority of PDD using 5-ALA compared with WL 
cystoscopy for the diagnosis and follow-up of ﬂ  at lesions 
such as CIS and moderate dysplasia has already been well 
documented (Riedl et al 2001; Zaak et al 2001, 2002; Filbeck 
et al 2002; Daniltchenko et al 2005)
Most of the studies conducted up to now have helped 
to establish the reliability of PDD performed by means of 
5-ALA as ﬁ  rst choice drug (Zaak et al 2005). However, some 
more recent investigations have documented the superiority 
of HAL over 5-ALA due to both enhanced ﬂ  uorescence and 
need for shorter drug instillation time (Filbeck et al 2003; 
Schmidbauer et al 2004; Jochamn et al 2005; Loidl et al 
2005; Witjes et al 2005). When using HAL, Schidbauer 
et al (2004) showed that among 83 patients with CIS, the 
diagnosis could be obtained by HAL cystoscopy only in 18 
(22%), by both standard and HAL cystoscopy in 62 (75%), 
and by standard cystoscopy only in 2 (2%). According to this 
experience, PDD cystoscopy was able to detect 28% more 
patients with CIS compared with WL cystoscopy.
In a multicenter study using HAL and involving 146 
patients, Jocham et al (2005) described an important 
improvement using PDD, accounting for an additional 
detection in 38 cases (24.4%). Based on this result, the 
authors could usefully influence both intra- and post-
operative management in a consistent number (17%) of their 
cases. In spite of this evidence, at present only a few centers 
in Europe are equipped for the PDD procedure and even 
Table 2 Carcinoma in situ detection
Positive urinary cytology  15 (30.6%)
Total CIS diagnosed  18 (36.7%)
CIS diagnosed with PDD +  4 (8.2%)
Standard WL cystoscopy
CIS diagnosed only with PDD  14 (28.5%)
CIS diagnosed with WL only  0
Overall PDD false positives  9 (33.3%)
Overall WL false positives  1 (7.1%)
Abbreviations: CIS, carcinoma in situ; PDD, photodynamic diagnosis; WL, white 
light.Therapeutics and Clinical Risk Management 2007:3(6) 1006
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fewer routinely perform PDD. We can assume that the most 
important limiting factors are: cost for the start-up treatment 
(dedicated equipment); cost and availability of ﬂ  uorescent 
drugs; necessity to plan the procedure in advance; and the 
need for some training in its. In order to answer the question 
concerning the cost/beneﬁ  t balance of this procedure, the 
deﬁ  nition of a widely accepted algorithm which deﬁ  nes 
when PDD should be recommended becomes of pivotal 
importance. Currently, the most evident clinical impact of 
PDD has been demonstrated for a) the management of any 
form of CIS, b) T1G3 patients in follow-up after TUR, c) 
multifocal disease during TUR or follow-up.
From the beginning of our practice, we decided to system-
atically perform PDD investigation for patients suffering from 
CIS alone in follow-up during BCG maintenance treatment. 
At evaluation time, out of an overall 49 patients, 15 presented 
with positive cytology while 18 were diagnosed with CIS at 
biopsies. Out of all the patients diagnosed with CIS, 14 were 
detected by means of PDD only and 4 by PDD + WL cystos-
copy, a surprisingly higher additional detection rate in favor of 
PDD. On this basis, the detection rate of WL cystoscopy was 
consistently lower than that usually reported in the literature 
(Sylvester et al 2005), suggesting again its controversial role 
for the management of patients undergoing BCG treatment. A 
possible reason for these results could be related to the relatively 
low number of patients enrolled per arm. When compared with 
the number of positive cytology cases, PDD-guided biopsies 
achieved an additional detection rate of 20%. Furthermore, 
according to our experience, when a positive cytology exists 
alongside negative biopsies at PDD, a CIS of the upper urinary 
tract should be suspected .
On the other hand, due to the higher PDD sensitivity 
documented in this study and in accordance with Kriegmair 
et al (2002), one can assume that, in cases of complete 
negative cystoscopy both in white and blue light, bladder 
mapping can be safely avoided.
In addition, the higher reliability of PDD compared with 
standard WL cystoscopy for the diagnosis of CIS in patients 
under BCG treatment appears to be evident regardless of 
the overall number of instillations performed during the 
SWOG schedule of administration. Photodynamic diagnosis 
performed using HAL together with biopsies taken by TUR 
seemed to achieve a higher CIS detection-rate than that 
obtained using 5-ALA and cold cup biopsies. On the other 
hand, a consistent overall rate of false positives (32.1%) 
was registered for PDD regardless of the method used. 
However, multicenter, randomized studies comparing the 
two drugs are needed to accurately assess any differences 
in detection rate. In order to reduce the incidence of false 
positive ﬁ  ndings, Grimbergen et al (2003) proposed a cut off 
period of 6 months after the last instillation as the suitable 
time for performing a reliable PDD cystoscopy. However, the 
key question is whether the beneﬁ  t of an early detection and 
an adequate management of a potential aggressive disease 
such as CIS could be preferable to the risk of performing 
useless biopsies.
Based on this experience we can assume that: the detec-
tion rate of PDD cystoscopy is higher than that provided by 
urinary cytology; WL cystoscopy alone is not reliable for 
the follow-up of CIS under BCG treatment; the overall side 
effects of PDD are negligible; PDD with HAL associated 
with TUR seems to be superior to PDD with 5-ALA asso-
ciated with cold cup biopsies. However, there is no doubt 
that this study suffers from many limitations, pitfalls, and 
potential biases related to the different variables presented. 
We are certainly aware that these results should be considered 
only as preliminary and need to be conﬁ  rmed by studies with 
a large series of patients.
Conclusions
The high recurrence rate of non-muscle invasive bladder 
cancer, up to 70% at 5 years, is clearly responsible for the 
high prevalence and social cost of this disease and represents 
a huge workload for urologists as well as a dramatic incon-
venience for patients. There is no doubt that novel diagnostic 
and therapeutic approaches are urgently needed.
During the last decade, the role of PDD has progressively 
increased for both treatment and the surveillance of patients 
with transitional cell carcinoma of the bladder. Many stud-
ies have clearly proved that PDD-guided cystoscopy using 
5-ALA can signiﬁ  cantly improve the overall detection rate 
of tumors, especially when ﬂ  at otherwise invisible lesions 
are in question. CIS is notoriously difﬁ  cult to recognize 
during standard WL cystoscopy, as it can generally appear 
macroscopically identical to normal urothelium. However, 
it is also well known that the progression rate of untreated 
CIS to invasive disease is about 50% and missed cases may 
be responsible for progression in otherwise low-risk patients. 
As well as CIS, there have been reports that PDD can be used 
to detect bladder dysplasia with much greater sensitivity than 
WL cytoscopy. The signiﬁ  cance of this outcome remains 
uncertain; however, since evidence suggests that dysplasia 
is frequently associated with progression of non-muscle 
invasive tumor disease, it will be of interest to investigate 
whether the increased detection of severe dysplasia could 
allow for a better deﬁ  nition of this controversial issue.Therapeutics and Clinical Risk Management 2007:3(6) 1007
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A recognized limitation of PDD cystoscopy is represented 
by the increased rate of false positive results when compared 
with standard WL cytoscopy. This limitation becomes cru-
cial in conditions such as acute and chronic inﬂ  ammation of 
bladder mucosa and when intravesical chemo-or immuno-
prophylaxis of recurrence after transurethral resection is 
ongoing.
Previous experience showed that patients who had under-
gone recent intravesical chemotherapy (within 6 months) had 
signiﬁ  cantly more false-positive biopsies at PDD cystoscopy 
than those for whom more than 6 months had elapsed since 
local therapy or who had never had it.
Our study, which was designed especially to investigate 
the actual role of PDD for the detection of failures in an 
homogeneous series of patients suffering from CIS during 
maintenance intravesical BCG treatment, seems to demon-
strate that PDD can signiﬁ  cantly increase the detection rate 
of CIS also in this special cohort of high risk patients.
In addition, our study conﬁ  rmed that PDD is a safe and 
relatively easy procedure to learn.
However, in spite of all the mentioned advantages, at 
present the PDD technique is not in widespread use. As a 
limiting factor, apart from the cost for PDD equipment and 
limited availability of the ﬂ  uorescent drugs, the fact that 
clinicians are still unsure of exactly which patient subgroups 
are best candidates for this technique probably plays a crucial 
role. Moreover, an accurate cost/effectiveness analysis of this 
procedure is still lacking in the literature (Colombo 2007).
Prospective and multicenter studies with long-term follow 
up are needed in order to determine the global impact of the 
improved tumor detection rate using PDD on recurrence, 
progression, and survival.
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